11-28-2008, 12:09 AM
5. All of the following are true of dual-antiplatelet therapy
with aspirin and clopidogrel except:
a) It lowers the risk of stent thrombosis and adverse
cardiac events in patients who have undergone
percutaneous coronary intervention.
b) It is more effective than aspirin alone at lowering
the risk of atherothrombotic events in patients
with stable cardiovascular disease or multiple risk
factorsc) It is associated with an increased risk of bleeding
in the elderly (age gt 75 years) with acute coronary
syndromes.
d) It may both safely and effectively reduce mortality
and the occurrence of major adverse vascular
events in patients presenting with acute MI.
e) Desensitization for clopidogrel-sensitive patients
appears safe and highly effective in inducing a
sustained remission for patients who require prolonged
therapy after drug-eluting stents.
with aspirin and clopidogrel except:
a) It lowers the risk of stent thrombosis and adverse
cardiac events in patients who have undergone
percutaneous coronary intervention.
b) It is more effective than aspirin alone at lowering
the risk of atherothrombotic events in patients
with stable cardiovascular disease or multiple risk
factorsc) It is associated with an increased risk of bleeding
in the elderly (age gt 75 years) with acute coronary
syndromes.
d) It may both safely and effectively reduce mortality
and the occurrence of major adverse vascular
events in patients presenting with acute MI.
e) Desensitization for clopidogrel-sensitive patients
appears safe and highly effective in inducing a
sustained remission for patients who require prolonged
therapy after drug-eluting stents.